Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1037 results
June 2022
-
Media ReleaseNovartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemiaWith unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at…
-
Media ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatmentsNovartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD…
-
Media ReleaseNovartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumorsTafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with…
-
Media ReleaseNovartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancerTabrecta® (capmatinib) provides a new targeted therapy option for previously-treated patients in Europe who are living with advanced non-small cell lung cancer (NSCLC) harboring alterations leading…
-
Key ReleaseNovartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patentAd hoc announcement pursuant to Art. 53 LRBasel, June 21, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding…
-
Media ReleaseNovartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomaticallyNearly all children with two and three copies of the SMN2 gene treated presymptomatically achieved age-appropriate milestones, including sitting, standing and walking. All children were free of…
-
Media ReleaseSandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMASubmission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced…
-
Media ReleaseNew research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equityCOVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband…
-
Media ReleaseNovartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALLIn final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…
-
Media ReleaseNovartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trialScemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
-
Media ReleaseNovartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III studyTreatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
-
Media ReleaseNew Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancerBiomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- …
- 87
- › Next page